Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study.
Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation.
Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).
Clinical Profiles and Short-Term Outcomes of Acute Disseminated Encephalomyelitis in Adult Chinese Patients.
Neurological Disease as a Failure of Brain-Immune Crosstalk: The Multiple Faces of Neuroinflammation.
Myelin plasticity in the central nervous system.
Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging.
Whole brain MP2RAGE-based mapping of the longitudinal relaxation time at 9.4T.
Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
Corrigendum.
Pathology and MRI: exploring cognitive impairment in MS.
Stem Cells Therapy in Multiple Sclerosis - A New Hope for Progressive Forms.
Immunoadsorption in patients with neuromyelitis optica spectrum disorder.
Age-related myelin degradation burdens the clearance function of microglia during aging.
Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.
N98S mutation in NEFL gene is dominantly inherited with a phenotype of polyneuropathy and cerebellar atrophy.
The Impact of MS-Related Cognitive Fatigue on Future Brain Parenchymal Loss and Relapse: A 17-Month Follow-up Study.
Neutrophils and viral-induced neurologic disease.
Olig2-Targeted G-Protein-Coupled Receptor Gpr17 Regulates Oligodendrocyte Survival in Response to Lysolecithin-Induced Demyelination.
"Gadolinium-Phobia:" Not a Helpful "Criterion" for Indication for Gadolinium-based Contrast Agent Administration in Multiple Sclerosis.
Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial.
The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.
Impact of Minocycline on Extracellular Matrix Metalloproteinase Inducer, a Factor Implicated in Multiple Sclerosis Immunopathogenesis.
Safety of monoclonal antibodies for the treatment of multiple sclerosis.
The patient's perspective: How to create awareness for improving access to care and treatment of MS patients?

Pages